×
The World Health Organization has set an ambitious target: to eliminate viral hepatitis as a public health threat by 2030. Achieving this goal requires widespread and accessible screening, especially since hepatitis C virus (HCV) infections are often asymptomatic.
Hytest is proud to introduce new recombinant HCV antigens, high-purity antigens developed as capture or detection material for use in immunoassays designed to qualitatively detect antibodies to HCV.
The U.S. CDC recommends that all adults should be screened for HCV at least once in their lifetime, except in settings where the prevalence is below 0.1%. The recommended first-line test is an FDA-approved anti-HCV antibody assay, followed by nucleic acid testing to confirm active infection, especially for those who are immunocompromised or recently exposed
New from Hytest: High-Quality Recombinant HCV antigens!
Hytest is proud to introduce new recombinant HCV antigens, high-purity antigens developed as capture or detection material for use in immunoassays designed to qualitatively detect antibodies to HCV. These are ideal choice for customers working on ELISA, LF, CLIA platforms. These reagents support the creation of sensitive, specific, and reliable diagnostic solutions that align with global HCV screening and elimination strategies.
Copyright © Hytest Ltd.